Please use this identifier to cite or link to this item: https://covid-19.conacyt.mx/jspui/handle/1000/3348
Target Virus or Target Ourselves for COVID-19 Drugs Discovery?-Lessons learned from anti-influenzas virus therapies
Liao Jiayu.
Way George.
Madahar Vipul.
Acceso Abierto
Atribución-NoComercial-SinDerivadas
10.1016/j.medidd.2020.100037
The COVID-19 pandemic, after it was reported in December 2019, is a highly contagious and now spreading to over 190 countries, causing a severe public health burden. Currently, there is no vaccine or specific drug to treat COVID-19, which is caused by a novel coronavirus, SARS-2-CoV. For this emergency, the FDA has approved Remdesivir and Hydroxychloroquine for treatment of COVID-19 as Emergency Use Authorization. However, even after this pandemic, COVID-19 may still have a chance to come back. Therefore, we need to come out with new strategies for drug discovery for combating COVID-19 in the future.
Medicine in Drug Discovery
2020
Artículo
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153514/pdf/main.pdf
Inglés
VIRUS RESPIRATORIOS
Appears in Collections:Artículos científicos

Upload archives


File SizeFormat 
1104088.pdf314.35 kBAdobe PDFView/Open